Bimagrumab

Bimagrumab (Anti-ACVR2B Reference Antibody) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness[1][2].

Product Specifications

CAS Number

[1356922-05-8]

Product Name Alternative

Anti-ACVR2B Reference Antibody; BYM338

UNSPSC

12352203

Target

TGF-β Receptor

Type

Inhibitory Antibodies

Related Pathways

TGF-beta/Smad

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/bimagrumab.html

Purity

99.31

Solubility

H2O

Smiles

[Bimagrumab]

Molecular Weight

(142.78 kDa)

References & Citations

[1]Heymsfield SB, et, al. Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial. JAMA Netw Open. 2021 Jan 4;4 (1) :e2033457. |[2]Lach-Trifilieff E, et, al. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Mol Cell Biol. 2014 Feb;34 (4) :606-18.